Print Share Email Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Kneebusch J. Kneebusch J Kneebusch, Jamie. Daridorexant (Quviviq®): A Dual Orexin Receptor Antagonist for Adults with Insomnia. PPP Updates, 21 November 2022. McGraw Hill, 2022. Pharmacotherapy Principles & Practice. https://ppp.mhmedical.com/updatesContent.aspx?gbosid=605140§ionid=273050297APA Citation Kneebusch J. Kneebusch J Kneebusch, Jamie. (2022). Daridorexant (quviviq®): a dual orexin receptor antagonist for adults with insomnia. [publicationyear2] Ppp updates. McGraw Hill. https://ppp.mhmedical.com/updatesContent.aspx?gbosid=605140§ionid=273050297.MLA Citation Kneebusch J. Kneebusch J Kneebusch, Jamie. "Daridorexant (Quviviq®): A Dual Orexin Receptor Antagonist for Adults with Insomnia." PPP Updates McGraw Hill, 2022, https://ppp.mhmedical.com/updatesContent.aspx?gbosid=605140§ionid=273050297. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Annotate Clip Autosuggest Results Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Download the Access App: iOS | Android Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.